Drug

Tislelizumab clinical trials

Also written BGB-A317, Tevimbra and VDT482.

studies test it: 398
open now: 214
in phase 3: 41
first study started: 2015

Keep track of what changes. Save the tislelizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

398 studies that test it; most in 2022 (68)

Studies that test tislelizumab, by start year
Year	Studies
2015	1
2016	3
2017	6
2018	11
2019	10
2020	32
2021	56
2022	68
2023	64
2024	50
2025	65
2026	32

By phase

A phase 1/2 study counts in both.

Early Phase 1: 4
Phase 1: 77
Phase 2: 294
Phase 3: 41
Phase 4: 8
No phase: 11

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular: 35
Carcinoma, Non-Small-Cell Lung: 31
Colorectal Neoplasms: 27
Esophageal Squamous Cell Carcinoma: 25
Stomach Neoplasms: 19
Squamous Cell Carcinoma of Head and Neck: 13
Neoplasms: 13
Small Cell Lung Carcinoma: 11
Triple Negative Breast Neoplasms: 11
Rectal Neoplasms: 11
Carcinoma: 10
Cholangiocarcinoma: 8

Who runs them

Industry 85 · Other 313

BeiGene (51) · Fudan University (27) · Sun Yat-sen University (16) · Fujian Cancer Hospital (15) · Tianjin Medical University Cancer Institute and Hospital (14) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (7) · Shanghai Zhongshan Hospital (7) · West China Hospital (6)

Often tested with

Tested in the same studies.

Paclitaxel (39) · Cisplatin (27) · Albumin-Bound Paclitaxel (23) · Lenvatinib (23) · Carboplatin (17) · Bevacizumab (16) · Gemcitabine (15) · HMPL-013 (13)

Studies

Open first, then newest update. How each study uses tislelizumab is read from its arms, and is right about nine times in ten.

Testing it · 398

See all 398 studies that test tislelizumab →

Given in every arm · 103 — tislelizumab is usual care beside what is tested

Showing 20 of 103.

As the comparator · 19 — what is tested is compared with tislelizumab

Codes

What other systems call tislelizumab · ClinicalTrials.gg INT001346

MeSH (NLM) C000707970tislelizumabConfirmed ClinicalTrials.gov, NLM
UNII (FDA) 0KVO411B3NTISLELIZUMABConfirmed FDA, NLM, Wikidata
Wikidata Q28209583tislelizumabConfirmed FDA, NLM, Wikidata
NCI Thesaurus C121775TislelizumabOne source FDA
DrugBank DB14922One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C000707970	tislelizumab	Confirmed ClinicalTrials.gov, NLM
UNII (FDA)	0KVO411B3N	TISLELIZUMAB	Confirmed FDA, NLM, Wikidata
Wikidata	Q28209583	tislelizumab	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C121775	Tislelizumab	One source FDA
DrugBank	DB14922	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.